nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP2C9—Capecitabine—colon cancer	0.0323	0.265	CbGbCtD
Bortezomib—CYP2C8—Fluorouracil—colon cancer	0.0275	0.225	CbGbCtD
Bortezomib—CYP1A2—Fluorouracil—colon cancer	0.0213	0.174	CbGbCtD
Bortezomib—CYP2C9—Fluorouracil—colon cancer	0.0192	0.157	CbGbCtD
Bortezomib—CYP3A4—Irinotecan—colon cancer	0.0116	0.0952	CbGbCtD
Bortezomib—CYP3A4—Vincristine—colon cancer	0.0101	0.0832	CbGbCtD
Bortezomib—PSMA1—embryo—colon cancer	0.00654	0.0352	CbGeAlD
Bortezomib—PSMA1—epithelium—colon cancer	0.00533	0.0287	CbGeAlD
Bortezomib—PSMB8—Vinorelbine—Vincristine—colon cancer	0.00504	1	CbGdCrCtD
Bortezomib—PSMA1—renal system—colon cancer	0.00495	0.0266	CbGeAlD
Bortezomib—PSMD2—embryo—colon cancer	0.00486	0.0262	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—colon cancer	0.00432	0.0232	CbGeAlD
Bortezomib—CTSG—lymphoid tissue—colon cancer	0.00428	0.023	CbGeAlD
Bortezomib—PSMA1—lymphoid tissue—colon cancer	0.00411	0.0221	CbGeAlD
Bortezomib—PSMA1—digestive system—colon cancer	0.00406	0.0218	CbGeAlD
Bortezomib—CTSG—bone marrow—colon cancer	0.0039	0.021	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—colon cancer	0.00382	0.0206	CbGeAlD
Bortezomib—PSMA1—bone marrow—colon cancer	0.00374	0.0201	CbGeAlD
Bortezomib—CTSG—vagina—colon cancer	0.00373	0.0201	CbGeAlD
Bortezomib—PSMB1—embryo—colon cancer	0.00373	0.0201	CbGeAlD
Bortezomib—PSMD2—renal system—colon cancer	0.00368	0.0198	CbGeAlD
Bortezomib—PSMB2—embryo—colon cancer	0.00364	0.0196	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—colon cancer	0.00336	0.0181	CbGeAlD
Bortezomib—PSMD1—bone marrow—colon cancer	0.00314	0.0169	CbGeAlD
Bortezomib—PSMD2—lymphoid tissue—colon cancer	0.00306	0.0164	CbGeAlD
Bortezomib—PSMA1—liver—colon cancer	0.00302	0.0163	CbGeAlD
Bortezomib—PSMD2—digestive system—colon cancer	0.00302	0.0162	CbGeAlD
Bortezomib—PSMD1—vagina—colon cancer	0.00301	0.0162	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—colon cancer	0.00293	0.0158	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—colon cancer	0.00286	0.0154	CbGeAlD
Bortezomib—PSMB1—renal system—colon cancer	0.00282	0.0152	CbGeAlD
Bortezomib—PSMD2—bone marrow—colon cancer	0.00278	0.015	CbGeAlD
Bortezomib—PSMB8—bone marrow—colon cancer	0.00277	0.0149	CbGeAlD
Bortezomib—PSMB2—renal system—colon cancer	0.00275	0.0148	CbGeAlD
Bortezomib—PSMD2—vagina—colon cancer	0.00267	0.0143	CbGeAlD
Bortezomib—PSMB8—vagina—colon cancer	0.00265	0.0143	CbGeAlD
Bortezomib—PSMD1—liver—colon cancer	0.00254	0.0137	CbGeAlD
Bortezomib—PSMB5—bone marrow—colon cancer	0.00244	0.0131	CbGeAlD
Bortezomib—CTSG—lymph node—colon cancer	0.00241	0.013	CbGeAlD
Bortezomib—SLC31A1—renal system—colon cancer	0.00239	0.0128	CbGeAlD
Bortezomib—PSMB1—lymphoid tissue—colon cancer	0.00234	0.0126	CbGeAlD
Bortezomib—PSMB5—vagina—colon cancer	0.00234	0.0126	CbGeAlD
Bortezomib—PSMA1—lymph node—colon cancer	0.00232	0.0125	CbGeAlD
Bortezomib—PSMB1—digestive system—colon cancer	0.00232	0.0125	CbGeAlD
Bortezomib—PSMB2—lymphoid tissue—colon cancer	0.00229	0.0123	CbGeAlD
Bortezomib—PSMB2—digestive system—colon cancer	0.00226	0.0122	CbGeAlD
Bortezomib—PSMD2—liver—colon cancer	0.00225	0.0121	CbGeAlD
Bortezomib—PSMB8—liver—colon cancer	0.00223	0.012	CbGeAlD
Bortezomib—PSMB1—bone marrow—colon cancer	0.00213	0.0115	CbGeAlD
Bortezomib—PSMB2—bone marrow—colon cancer	0.00208	0.0112	CbGeAlD
Bortezomib—PSMB1—vagina—colon cancer	0.00205	0.011	CbGeAlD
Bortezomib—PSMB2—vagina—colon cancer	0.002	0.0107	CbGeAlD
Bortezomib—PSMB5—liver—colon cancer	0.00197	0.0106	CbGeAlD
Bortezomib—SLC31A1—digestive system—colon cancer	0.00196	0.0105	CbGeAlD
Bortezomib—PSMD1—lymph node—colon cancer	0.00195	0.0105	CbGeAlD
Bortezomib—SLC31A1—bone marrow—colon cancer	0.0018	0.00971	CbGeAlD
Bortezomib—SLC31A1—vagina—colon cancer	0.00173	0.0093	CbGeAlD
Bortezomib—PSMB1—liver—colon cancer	0.00173	0.00929	CbGeAlD
Bortezomib—PSMD2—lymph node—colon cancer	0.00172	0.00928	CbGeAlD
Bortezomib—PSMB8—lymph node—colon cancer	0.00171	0.00922	CbGeAlD
Bortezomib—PTGS1—endothelium—colon cancer	0.00171	0.0092	CbGeAlD
Bortezomib—PSMB2—liver—colon cancer	0.00168	0.00906	CbGeAlD
Bortezomib—PTGS1—blood vessel—colon cancer	0.00158	0.00849	CbGeAlD
Bortezomib—PSMB5—lymph node—colon cancer	0.00151	0.00814	CbGeAlD
Bortezomib—SLC31A1—liver—colon cancer	0.00146	0.00785	CbGeAlD
Bortezomib—Nateglinide—PPARG—colon cancer	0.00136	1	CrCbGaD
Bortezomib—PSMB1—lymph node—colon cancer	0.00132	0.00712	CbGeAlD
Bortezomib—PSMB2—lymph node—colon cancer	0.00129	0.00695	CbGeAlD
Bortezomib—SLC31A1—lymph node—colon cancer	0.00112	0.00602	CbGeAlD
Bortezomib—CYP2C8—renal system—colon cancer	0.000878	0.00472	CbGeAlD
Bortezomib—CYP1A1—epithelium—colon cancer	0.000874	0.0047	CbGeAlD
Bortezomib—CYP2C19—digestive system—colon cancer	0.000825	0.00444	CbGeAlD
Bortezomib—CYP1A2—renal system—colon cancer	0.000821	0.00442	CbGeAlD
Bortezomib—CYP1A1—renal system—colon cancer	0.00081	0.00436	CbGeAlD
Bortezomib—PTGS1—epithelium—colon cancer	0.000767	0.00413	CbGeAlD
Bortezomib—PTGS1—smooth muscle tissue—colon cancer	0.00074	0.00398	CbGeAlD
Bortezomib—CYP2C19—vagina—colon cancer	0.000728	0.00392	CbGeAlD
Bortezomib—PTGS1—renal system—colon cancer	0.000712	0.00383	CbGeAlD
Bortezomib—CYP1A2—digestive system—colon cancer	0.000674	0.00363	CbGeAlD
Bortezomib—CYP1A1—digestive system—colon cancer	0.000665	0.00358	CbGeAlD
Bortezomib—CYP2C9—digestive system—colon cancer	0.00064	0.00344	CbGeAlD
Bortezomib—CYP2C8—vagina—colon cancer	0.000636	0.00342	CbGeAlD
Bortezomib—CYP2C19—liver—colon cancer	0.000615	0.00331	CbGeAlD
Bortezomib—CYP3A4—renal system—colon cancer	0.000595	0.0032	CbGeAlD
Bortezomib—CYP1A1—vagina—colon cancer	0.000587	0.00316	CbGeAlD
Bortezomib—CYP2D6—renal system—colon cancer	0.000585	0.00315	CbGeAlD
Bortezomib—PTGS1—digestive system—colon cancer	0.000584	0.00314	CbGeAlD
Bortezomib—CYP2C8—liver—colon cancer	0.000536	0.00289	CbGeAlD
Bortezomib—PTGS1—vagina—colon cancer	0.000516	0.00277	CbGeAlD
Bortezomib—CYP1A2—liver—colon cancer	0.000502	0.0027	CbGeAlD
Bortezomib—CYP1A1—liver—colon cancer	0.000495	0.00266	CbGeAlD
Bortezomib—CYP3A4—digestive system—colon cancer	0.000488	0.00262	CbGeAlD
Bortezomib—CYP2D6—digestive system—colon cancer	0.00048	0.00258	CbGeAlD
Bortezomib—CYP2C9—liver—colon cancer	0.000476	0.00256	CbGeAlD
Bortezomib—CYP1A1—lymph node—colon cancer	0.00038	0.00204	CbGeAlD
Bortezomib—CYP3A4—liver—colon cancer	0.000363	0.00196	CbGeAlD
Bortezomib—CYP2D6—liver—colon cancer	0.000358	0.00192	CbGeAlD
Bortezomib—PTGS1—lymph node—colon cancer	0.000334	0.00179	CbGeAlD
Bortezomib—Hyperhidrosis—Vincristine—colon cancer	0.000217	0.000569	CcSEcCtD
Bortezomib—Hepatobiliary disease—Capecitabine—colon cancer	0.000217	0.000569	CcSEcCtD
Bortezomib—Epistaxis—Capecitabine—colon cancer	0.000216	0.000568	CcSEcCtD
Bortezomib—Discomfort—Fluorouracil—colon cancer	0.000216	0.000566	CcSEcCtD
Bortezomib—Shock—Irinotecan—colon cancer	0.000215	0.000564	CcSEcCtD
Bortezomib—Nervous system disorder—Irinotecan—colon cancer	0.000214	0.000563	CcSEcCtD
Bortezomib—Thrombocytopenia—Irinotecan—colon cancer	0.000214	0.000562	CcSEcCtD
Bortezomib—Anorexia—Vincristine—colon cancer	0.000214	0.000562	CcSEcCtD
Bortezomib—Irritability—Methotrexate—colon cancer	0.000212	0.000555	CcSEcCtD
Bortezomib—Hyperhidrosis—Irinotecan—colon cancer	0.000211	0.000555	CcSEcCtD
Bortezomib—Confusional state—Fluorouracil—colon cancer	0.000211	0.000554	CcSEcCtD
Bortezomib—Hypotension—Vincristine—colon cancer	0.00021	0.00055	CcSEcCtD
Bortezomib—Bradycardia—Capecitabine—colon cancer	0.00021	0.00055	CcSEcCtD
Bortezomib—Anaphylactic shock—Fluorouracil—colon cancer	0.000209	0.000549	CcSEcCtD
Bortezomib—Oedema—Fluorouracil—colon cancer	0.000209	0.000549	CcSEcCtD
Bortezomib—Anorexia—Irinotecan—colon cancer	0.000208	0.000547	CcSEcCtD
Bortezomib—Ataxia—Methotrexate—colon cancer	0.000208	0.000547	CcSEcCtD
Bortezomib—Infection—Fluorouracil—colon cancer	0.000208	0.000546	CcSEcCtD
Bortezomib—Haemoglobin—Capecitabine—colon cancer	0.000207	0.000543	CcSEcCtD
Bortezomib—Hepatitis—Capecitabine—colon cancer	0.000206	0.00054	CcSEcCtD
Bortezomib—Haemorrhage—Capecitabine—colon cancer	0.000206	0.00054	CcSEcCtD
Bortezomib—Nervous system disorder—Fluorouracil—colon cancer	0.000205	0.000539	CcSEcCtD
Bortezomib—Thrombocytopenia—Fluorouracil—colon cancer	0.000205	0.000538	CcSEcCtD
Bortezomib—Hypoaesthesia—Capecitabine—colon cancer	0.000205	0.000538	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000205	0.000537	CcSEcCtD
Bortezomib—Tachycardia—Fluorouracil—colon cancer	0.000204	0.000536	CcSEcCtD
Bortezomib—Hypotension—Irinotecan—colon cancer	0.000204	0.000536	CcSEcCtD
Bortezomib—Urinary tract disorder—Capecitabine—colon cancer	0.000203	0.000534	CcSEcCtD
Bortezomib—Insomnia—Vincristine—colon cancer	0.000203	0.000533	CcSEcCtD
Bortezomib—Oedema peripheral—Capecitabine—colon cancer	0.000203	0.000532	CcSEcCtD
Bortezomib—Connective tissue disorder—Capecitabine—colon cancer	0.000202	0.000531	CcSEcCtD
Bortezomib—Urethral disorder—Capecitabine—colon cancer	0.000202	0.00053	CcSEcCtD
Bortezomib—Paraesthesia—Vincristine—colon cancer	0.000202	0.000529	CcSEcCtD
Bortezomib—Breast disorder—Methotrexate—colon cancer	0.0002	0.000526	CcSEcCtD
Bortezomib—Anorexia—Fluorouracil—colon cancer	0.0002	0.000524	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.0002	0.000524	CcSEcCtD
Bortezomib—Visual impairment—Capecitabine—colon cancer	0.000199	0.000521	CcSEcCtD
Bortezomib—Insomnia—Irinotecan—colon cancer	0.000198	0.000519	CcSEcCtD
Bortezomib—Paraesthesia—Irinotecan—colon cancer	0.000196	0.000515	CcSEcCtD
Bortezomib—Hypotension—Fluorouracil—colon cancer	0.000196	0.000513	CcSEcCtD
Bortezomib—Decreased appetite—Vincristine—colon cancer	0.000195	0.000512	CcSEcCtD
Bortezomib—Dyspnoea—Irinotecan—colon cancer	0.000195	0.000511	CcSEcCtD
Bortezomib—Erythema multiforme—Capecitabine—colon cancer	0.000195	0.000511	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Vincristine—colon cancer	0.000194	0.000509	CcSEcCtD
Bortezomib—Fatigue—Vincristine—colon cancer	0.000194	0.000508	CcSEcCtD
Bortezomib—Eye disorder—Capecitabine—colon cancer	0.000192	0.000505	CcSEcCtD
Bortezomib—Dyspepsia—Irinotecan—colon cancer	0.000192	0.000505	CcSEcCtD
Bortezomib—Tinnitus—Capecitabine—colon cancer	0.000192	0.000504	CcSEcCtD
Bortezomib—Constipation—Vincristine—colon cancer	0.000192	0.000504	CcSEcCtD
Bortezomib—Pain—Vincristine—colon cancer	0.000192	0.000504	CcSEcCtD
Bortezomib—Flushing—Capecitabine—colon cancer	0.000191	0.000502	CcSEcCtD
Bortezomib—Cardiac disorder—Capecitabine—colon cancer	0.000191	0.000502	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000191	0.000501	CcSEcCtD
Bortezomib—Decreased appetite—Irinotecan—colon cancer	0.00019	0.000499	CcSEcCtD
Bortezomib—Insomnia—Fluorouracil—colon cancer	0.000189	0.000497	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000189	0.000495	CcSEcCtD
Bortezomib—Fatigue—Irinotecan—colon cancer	0.000189	0.000495	CcSEcCtD
Bortezomib—Paraesthesia—Fluorouracil—colon cancer	0.000188	0.000493	CcSEcCtD
Bortezomib—Pancreatitis—Methotrexate—colon cancer	0.000188	0.000493	CcSEcCtD
Bortezomib—Pain—Irinotecan—colon cancer	0.000187	0.000491	CcSEcCtD
Bortezomib—Constipation—Irinotecan—colon cancer	0.000187	0.000491	CcSEcCtD
Bortezomib—Angiopathy—Capecitabine—colon cancer	0.000187	0.00049	CcSEcCtD
Bortezomib—Dyspnoea—Fluorouracil—colon cancer	0.000187	0.00049	CcSEcCtD
Bortezomib—Immune system disorder—Capecitabine—colon cancer	0.000186	0.000488	CcSEcCtD
Bortezomib—Mediastinal disorder—Capecitabine—colon cancer	0.000186	0.000487	CcSEcCtD
Bortezomib—Chills—Capecitabine—colon cancer	0.000185	0.000485	CcSEcCtD
Bortezomib—Dyspepsia—Fluorouracil—colon cancer	0.000184	0.000484	CcSEcCtD
Bortezomib—Arrhythmia—Capecitabine—colon cancer	0.000184	0.000483	CcSEcCtD
Bortezomib—Abdominal discomfort—Methotrexate—colon cancer	0.000184	0.000482	CcSEcCtD
Bortezomib—Gastrointestinal pain—Vincristine—colon cancer	0.000184	0.000482	CcSEcCtD
Bortezomib—Decreased appetite—Fluorouracil—colon cancer	0.000182	0.000478	CcSEcCtD
Bortezomib—Pancytopenia—Methotrexate—colon cancer	0.000182	0.000477	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000181	0.000474	CcSEcCtD
Bortezomib—Mental disorder—Capecitabine—colon cancer	0.00018	0.000473	CcSEcCtD
Bortezomib—Feeling abnormal—Irinotecan—colon cancer	0.00018	0.000473	CcSEcCtD
Bortezomib—Erythema—Capecitabine—colon cancer	0.000179	0.00047	CcSEcCtD
Bortezomib—Malnutrition—Capecitabine—colon cancer	0.000179	0.00047	CcSEcCtD
Bortezomib—Neutropenia—Methotrexate—colon cancer	0.000179	0.00047	CcSEcCtD
Bortezomib—Pain—Fluorouracil—colon cancer	0.000179	0.00047	CcSEcCtD
Bortezomib—Gastrointestinal pain—Irinotecan—colon cancer	0.000179	0.000469	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000178	0.000467	CcSEcCtD
Bortezomib—Body temperature increased—Vincristine—colon cancer	0.000177	0.000466	CcSEcCtD
Bortezomib—Abdominal pain—Vincristine—colon cancer	0.000177	0.000466	CcSEcCtD
Bortezomib—Flatulence—Capecitabine—colon cancer	0.000177	0.000464	CcSEcCtD
Bortezomib—Erectile dysfunction—Methotrexate—colon cancer	0.000176	0.000463	CcSEcCtD
Bortezomib—Dysgeusia—Capecitabine—colon cancer	0.000176	0.000461	CcSEcCtD
Bortezomib—Photosensitivity reaction—Methotrexate—colon cancer	0.000175	0.000459	CcSEcCtD
Bortezomib—Back pain—Capecitabine—colon cancer	0.000173	0.000455	CcSEcCtD
Bortezomib—Body temperature increased—Irinotecan—colon cancer	0.000173	0.000454	CcSEcCtD
Bortezomib—Abdominal pain—Irinotecan—colon cancer	0.000173	0.000454	CcSEcCtD
Bortezomib—Feeling abnormal—Fluorouracil—colon cancer	0.000173	0.000453	CcSEcCtD
Bortezomib—Muscle spasms—Capecitabine—colon cancer	0.000172	0.000452	CcSEcCtD
Bortezomib—Pneumonia—Methotrexate—colon cancer	0.000172	0.000451	CcSEcCtD
Bortezomib—Infestation NOS—Methotrexate—colon cancer	0.000171	0.000448	CcSEcCtD
Bortezomib—Infestation—Methotrexate—colon cancer	0.000171	0.000448	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000169	0.000444	CcSEcCtD
Bortezomib—Vision blurred—Capecitabine—colon cancer	0.000169	0.000443	CcSEcCtD
Bortezomib—Tremor—Capecitabine—colon cancer	0.000168	0.000441	CcSEcCtD
Bortezomib—Renal failure—Methotrexate—colon cancer	0.000168	0.000441	CcSEcCtD
Bortezomib—Stomatitis—Methotrexate—colon cancer	0.000166	0.000437	CcSEcCtD
Bortezomib—Ill-defined disorder—Capecitabine—colon cancer	0.000166	0.000437	CcSEcCtD
Bortezomib—Urticaria—Fluorouracil—colon cancer	0.000166	0.000436	CcSEcCtD
Bortezomib—Conjunctivitis—Methotrexate—colon cancer	0.000166	0.000436	CcSEcCtD
Bortezomib—Anaemia—Capecitabine—colon cancer	0.000166	0.000435	CcSEcCtD
Bortezomib—Body temperature increased—Fluorouracil—colon cancer	0.000166	0.000434	CcSEcCtD
Bortezomib—Hypersensitivity—Vincristine—colon cancer	0.000165	0.000434	CcSEcCtD
Bortezomib—Haematuria—Methotrexate—colon cancer	0.000163	0.000427	CcSEcCtD
Bortezomib—Malaise—Capecitabine—colon cancer	0.000162	0.000424	CcSEcCtD
Bortezomib—Hepatobiliary disease—Methotrexate—colon cancer	0.000162	0.000424	CcSEcCtD
Bortezomib—Epistaxis—Methotrexate—colon cancer	0.000161	0.000423	CcSEcCtD
Bortezomib—Vertigo—Capecitabine—colon cancer	0.000161	0.000423	CcSEcCtD
Bortezomib—Hypersensitivity—Irinotecan—colon cancer	0.000161	0.000423	CcSEcCtD
Bortezomib—Asthenia—Vincristine—colon cancer	0.000161	0.000423	CcSEcCtD
Bortezomib—Syncope—Capecitabine—colon cancer	0.000161	0.000422	CcSEcCtD
Bortezomib—Leukopenia—Capecitabine—colon cancer	0.000161	0.000421	CcSEcCtD
Bortezomib—Palpitations—Capecitabine—colon cancer	0.000158	0.000416	CcSEcCtD
Bortezomib—Loss of consciousness—Capecitabine—colon cancer	0.000158	0.000413	CcSEcCtD
Bortezomib—Asthenia—Irinotecan—colon cancer	0.000157	0.000412	CcSEcCtD
Bortezomib—Cough—Capecitabine—colon cancer	0.000156	0.000411	CcSEcCtD
Bortezomib—Hypertension—Capecitabine—colon cancer	0.000155	0.000406	CcSEcCtD
Bortezomib—Hypersensitivity—Fluorouracil—colon cancer	0.000154	0.000405	CcSEcCtD
Bortezomib—Haemoglobin—Methotrexate—colon cancer	0.000154	0.000404	CcSEcCtD
Bortezomib—Diarrhoea—Vincristine—colon cancer	0.000154	0.000403	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—colon cancer	0.000153	0.000402	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—colon cancer	0.000153	0.000402	CcSEcCtD
Bortezomib—Arthralgia—Capecitabine—colon cancer	0.000153	0.000401	CcSEcCtD
Bortezomib—Myalgia—Capecitabine—colon cancer	0.000153	0.000401	CcSEcCtD
Bortezomib—Chest pain—Capecitabine—colon cancer	0.000153	0.000401	CcSEcCtD
Bortezomib—Anxiety—Capecitabine—colon cancer	0.000152	0.000399	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000152	0.000398	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—colon cancer	0.000151	0.000397	CcSEcCtD
Bortezomib—Discomfort—Capecitabine—colon cancer	0.000151	0.000396	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—colon cancer	0.00015	0.000394	CcSEcCtD
Bortezomib—Diarrhoea—Irinotecan—colon cancer	0.00015	0.000393	CcSEcCtD
Bortezomib—Dizziness—Vincristine—colon cancer	0.000148	0.00039	CcSEcCtD
Bortezomib—Pruritus—Fluorouracil—colon cancer	0.000148	0.000389	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—colon cancer	0.000148	0.000388	CcSEcCtD
Bortezomib—Confusional state—Capecitabine—colon cancer	0.000148	0.000387	CcSEcCtD
Bortezomib—Oedema—Capecitabine—colon cancer	0.000146	0.000384	CcSEcCtD
Bortezomib—Infection—Capecitabine—colon cancer	0.000145	0.000381	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—colon cancer	0.000145	0.00038	CcSEcCtD
Bortezomib—Dizziness—Irinotecan—colon cancer	0.000145	0.000379	CcSEcCtD
Bortezomib—Shock—Capecitabine—colon cancer	0.000144	0.000378	CcSEcCtD
Bortezomib—Nervous system disorder—Capecitabine—colon cancer	0.000144	0.000377	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—colon cancer	0.000143	0.000376	CcSEcCtD
Bortezomib—Diarrhoea—Fluorouracil—colon cancer	0.000143	0.000376	CcSEcCtD
Bortezomib—Thrombocytopenia—Capecitabine—colon cancer	0.000143	0.000376	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—colon cancer	0.000143	0.000375	CcSEcCtD
Bortezomib—Tachycardia—Capecitabine—colon cancer	0.000143	0.000375	CcSEcCtD
Bortezomib—Vomiting—Vincristine—colon cancer	0.000143	0.000375	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—colon cancer	0.000142	0.000373	CcSEcCtD
Bortezomib—Skin disorder—Capecitabine—colon cancer	0.000142	0.000373	CcSEcCtD
Bortezomib—Rash—Vincristine—colon cancer	0.000142	0.000371	CcSEcCtD
Bortezomib—Hyperhidrosis—Capecitabine—colon cancer	0.000141	0.000371	CcSEcCtD
Bortezomib—Dermatitis—Vincristine—colon cancer	0.000141	0.000371	CcSEcCtD
Bortezomib—Headache—Vincristine—colon cancer	0.000141	0.000369	CcSEcCtD
Bortezomib—Anorexia—Capecitabine—colon cancer	0.000139	0.000366	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—colon cancer	0.000139	0.000365	CcSEcCtD
Bortezomib—Vomiting—Irinotecan—colon cancer	0.000139	0.000365	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—colon cancer	0.000139	0.000363	CcSEcCtD
Bortezomib—Dizziness—Fluorouracil—colon cancer	0.000138	0.000363	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—colon cancer	0.000138	0.000363	CcSEcCtD
Bortezomib—Rash—Irinotecan—colon cancer	0.000138	0.000362	CcSEcCtD
Bortezomib—Dermatitis—Irinotecan—colon cancer	0.000138	0.000361	CcSEcCtD
Bortezomib—Chills—Methotrexate—colon cancer	0.000138	0.000361	CcSEcCtD
Bortezomib—Headache—Irinotecan—colon cancer	0.000137	0.000359	CcSEcCtD
Bortezomib—Hypotension—Capecitabine—colon cancer	0.000137	0.000359	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—colon cancer	0.000134	0.000352	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—colon cancer	0.000133	0.00035	CcSEcCtD
Bortezomib—Erythema—Methotrexate—colon cancer	0.000133	0.00035	CcSEcCtD
Bortezomib—Nausea—Vincristine—colon cancer	0.000133	0.00035	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000133	0.00035	CcSEcCtD
Bortezomib—Vomiting—Fluorouracil—colon cancer	0.000133	0.000349	CcSEcCtD
Bortezomib—Insomnia—Capecitabine—colon cancer	0.000132	0.000347	CcSEcCtD
Bortezomib—Rash—Fluorouracil—colon cancer	0.000132	0.000346	CcSEcCtD
Bortezomib—Dermatitis—Fluorouracil—colon cancer	0.000132	0.000346	CcSEcCtD
Bortezomib—Paraesthesia—Capecitabine—colon cancer	0.000131	0.000345	CcSEcCtD
Bortezomib—Headache—Fluorouracil—colon cancer	0.000131	0.000344	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—colon cancer	0.000131	0.000343	CcSEcCtD
Bortezomib—Dyspnoea—Capecitabine—colon cancer	0.00013	0.000342	CcSEcCtD
Bortezomib—Nausea—Irinotecan—colon cancer	0.00013	0.000341	CcSEcCtD
Bortezomib—Back pain—Methotrexate—colon cancer	0.000129	0.000339	CcSEcCtD
Bortezomib—Dyspepsia—Capecitabine—colon cancer	0.000129	0.000338	CcSEcCtD
Bortezomib—Decreased appetite—Capecitabine—colon cancer	0.000127	0.000334	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Capecitabine—colon cancer	0.000126	0.000331	CcSEcCtD
Bortezomib—Fatigue—Capecitabine—colon cancer	0.000126	0.000331	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—colon cancer	0.000126	0.00033	CcSEcCtD
Bortezomib—Constipation—Capecitabine—colon cancer	0.000125	0.000328	CcSEcCtD
Bortezomib—Pain—Capecitabine—colon cancer	0.000125	0.000328	CcSEcCtD
Bortezomib—Nausea—Fluorouracil—colon cancer	0.000124	0.000326	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—colon cancer	0.000124	0.000325	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—colon cancer	0.000123	0.000324	CcSEcCtD
Bortezomib—Feeling abnormal—Capecitabine—colon cancer	0.000121	0.000316	CcSEcCtD
Bortezomib—Malaise—Methotrexate—colon cancer	0.00012	0.000316	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—colon cancer	0.00012	0.000315	CcSEcCtD
Bortezomib—Gastrointestinal pain—Capecitabine—colon cancer	0.00012	0.000314	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—colon cancer	0.000119	0.000313	CcSEcCtD
Bortezomib—Cough—Methotrexate—colon cancer	0.000116	0.000306	CcSEcCtD
Bortezomib—Urticaria—Capecitabine—colon cancer	0.000116	0.000305	CcSEcCtD
Bortezomib—Abdominal pain—Capecitabine—colon cancer	0.000116	0.000304	CcSEcCtD
Bortezomib—Body temperature increased—Capecitabine—colon cancer	0.000116	0.000304	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—colon cancer	0.000116	0.000303	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—colon cancer	0.000114	0.000298	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—colon cancer	0.000114	0.000298	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—colon cancer	0.000114	0.000298	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000113	0.000296	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—colon cancer	0.000112	0.000295	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—colon cancer	0.00011	0.000288	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—colon cancer	0.000109	0.000286	CcSEcCtD
Bortezomib—Infection—Methotrexate—colon cancer	0.000108	0.000284	CcSEcCtD
Bortezomib—Hypersensitivity—Capecitabine—colon cancer	0.000108	0.000283	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—colon cancer	0.000107	0.00028	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—colon cancer	0.000107	0.00028	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—colon cancer	0.000106	0.000278	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—colon cancer	0.000105	0.000276	CcSEcCtD
Bortezomib—Asthenia—Capecitabine—colon cancer	0.000105	0.000275	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—colon cancer	0.000104	0.000272	CcSEcCtD
Bortezomib—Pruritus—Capecitabine—colon cancer	0.000104	0.000272	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—colon cancer	0.000102	0.000267	CcSEcCtD
Bortezomib—Diarrhoea—Capecitabine—colon cancer	0.0001	0.000263	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—colon cancer	9.93e-05	0.00026	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—colon cancer	9.85e-05	0.000259	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—colon cancer	9.78e-05	0.000257	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—colon cancer	9.71e-05	0.000255	CcSEcCtD
Bortezomib—Dizziness—Capecitabine—colon cancer	9.68e-05	0.000254	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—colon cancer	9.59e-05	0.000252	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—colon cancer	9.47e-05	0.000248	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—colon cancer	9.41e-05	0.000247	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—colon cancer	9.39e-05	0.000246	CcSEcCtD
Bortezomib—Pain—Methotrexate—colon cancer	9.32e-05	0.000244	CcSEcCtD
Bortezomib—Vomiting—Capecitabine—colon cancer	9.3e-05	0.000244	CcSEcCtD
Bortezomib—Rash—Capecitabine—colon cancer	9.23e-05	0.000242	CcSEcCtD
Bortezomib—Dermatitis—Capecitabine—colon cancer	9.22e-05	0.000242	CcSEcCtD
Bortezomib—Headache—Capecitabine—colon cancer	9.17e-05	0.000241	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—colon cancer	8.98e-05	0.000236	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—colon cancer	8.91e-05	0.000234	CcSEcCtD
Bortezomib—Nausea—Capecitabine—colon cancer	8.69e-05	0.000228	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—colon cancer	8.65e-05	0.000227	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—colon cancer	8.61e-05	0.000226	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—colon cancer	8.61e-05	0.000226	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—colon cancer	8.03e-05	0.000211	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—colon cancer	7.82e-05	0.000205	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—colon cancer	7.71e-05	0.000202	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—colon cancer	7.45e-05	0.000196	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—colon cancer	7.2e-05	0.000189	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—colon cancer	6.93e-05	0.000182	CcSEcCtD
Bortezomib—Rash—Methotrexate—colon cancer	6.87e-05	0.00018	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—colon cancer	6.86e-05	0.00018	CcSEcCtD
Bortezomib—Headache—Methotrexate—colon cancer	6.82e-05	0.000179	CcSEcCtD
Bortezomib—Nausea—Methotrexate—colon cancer	6.47e-05	0.00017	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—EP300—colon cancer	2.02e-05	6.63e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—colon cancer	2.01e-05	6.6e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—colon cancer	1.99e-05	6.55e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—colon cancer	1.98e-05	6.51e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SRC—colon cancer	1.98e-05	6.51e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—colon cancer	1.98e-05	6.48e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SRC—colon cancer	1.97e-05	6.48e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SRC—colon cancer	1.97e-05	6.45e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—colon cancer	1.93e-05	6.34e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KRAS—colon cancer	1.93e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KRAS—colon cancer	1.93e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KRAS—colon cancer	1.93e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—colon cancer	1.92e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—colon cancer	1.92e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—colon cancer	1.92e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—colon cancer	1.92e-05	6.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—colon cancer	1.92e-05	6.3e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—colon cancer	1.92e-05	6.3e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—colon cancer	1.92e-05	6.3e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—colon cancer	1.91e-05	6.28e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.91e-05	6.28e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NRAS—colon cancer	1.91e-05	6.27e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—AKT1—colon cancer	1.91e-05	6.26e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NRAS—colon cancer	1.9e-05	6.24e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—colon cancer	1.9e-05	6.23e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—AKT1—colon cancer	1.9e-05	6.23e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—colon cancer	1.9e-05	6.23e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—AKT1—colon cancer	1.9e-05	6.22e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—colon cancer	1.89e-05	6.21e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NRAS—colon cancer	1.89e-05	6.21e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—AKT1—colon cancer	1.89e-05	6.2e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—AKT1—colon cancer	1.89e-05	6.19e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—colon cancer	1.88e-05	6.18e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—colon cancer	1.88e-05	6.18e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—colon cancer	1.88e-05	6.18e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—AKT1—colon cancer	1.88e-05	6.17e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—colon cancer	1.86e-05	6.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—EP300—colon cancer	1.85e-05	6.07e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—EP300—colon cancer	1.85e-05	6.07e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—EP300—colon cancer	1.85e-05	6.07e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.84e-05	6.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—EP300—colon cancer	1.82e-05	5.98e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PIK3CA—colon cancer	1.81e-05	5.92e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PIK3CA—colon cancer	1.8e-05	5.9e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PIK3CA—colon cancer	1.79e-05	5.87e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—colon cancer	1.78e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—colon cancer	1.78e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—colon cancer	1.78e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—colon cancer	1.78e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—colon cancer	1.77e-05	5.82e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—colon cancer	1.77e-05	5.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PIK3CA—colon cancer	1.77e-05	5.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PIK3CA—colon cancer	1.77e-05	5.81e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PIK3CA—colon cancer	1.77e-05	5.81e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—colon cancer	1.77e-05	5.79e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—colon cancer	1.76e-05	5.78e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—colon cancer	1.76e-05	5.78e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—colon cancer	1.76e-05	5.77e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—colon cancer	1.75e-05	5.75e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—colon cancer	1.75e-05	5.75e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.74e-05	5.73e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PIK3CA—colon cancer	1.74e-05	5.73e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—colon cancer	1.74e-05	5.72e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—colon cancer	1.74e-05	5.71e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—colon cancer	1.73e-05	5.68e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CASP3—colon cancer	1.73e-05	5.66e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CASP3—colon cancer	1.73e-05	5.66e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CASP3—colon cancer	1.73e-05	5.66e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—colon cancer	1.72e-05	5.65e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CASP3—colon cancer	1.7e-05	5.59e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.69e-05	5.53e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—colon cancer	1.68e-05	5.51e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—colon cancer	1.68e-05	5.51e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—colon cancer	1.68e-05	5.51e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CTNNB1—colon cancer	1.66e-05	5.46e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CTNNB1—colon cancer	1.66e-05	5.46e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CTNNB1—colon cancer	1.66e-05	5.46e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—colon cancer	1.66e-05	5.44e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—colon cancer	1.64e-05	5.39e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CTNNB1—colon cancer	1.64e-05	5.38e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—colon cancer	1.64e-05	5.37e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—colon cancer	1.64e-05	5.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—colon cancer	1.64e-05	5.37e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—colon cancer	1.64e-05	5.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PIK3CA—colon cancer	1.63e-05	5.36e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PIK3CA—colon cancer	1.63e-05	5.36e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PIK3CA—colon cancer	1.63e-05	5.36e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—colon cancer	1.63e-05	5.34e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1A—colon cancer	1.63e-05	5.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1A—colon cancer	1.63e-05	5.33e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1A—colon cancer	1.63e-05	5.33e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—colon cancer	1.61e-05	5.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—colon cancer	1.61e-05	5.29e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.61e-05	5.27e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1A—colon cancer	1.6e-05	5.26e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EP300—colon cancer	1.55e-05	5.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EP300—colon cancer	1.55e-05	5.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EP300—colon cancer	1.55e-05	5.08e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.53e-05	5.02e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EP300—colon cancer	1.52e-05	5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—colon cancer	1.51e-05	4.96e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—colon cancer	1.51e-05	4.96e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—colon cancer	1.51e-05	4.96e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—colon cancer	1.51e-05	4.95e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.5e-05	4.94e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SRC—colon cancer	1.5e-05	4.94e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SRC—colon cancer	1.5e-05	4.94e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SRC—colon cancer	1.5e-05	4.94e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—colon cancer	1.5e-05	4.93e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ABCB1—colon cancer	1.5e-05	4.91e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—colon cancer	1.5e-05	4.91e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.49e-05	4.89e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—colon cancer	1.49e-05	4.89e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SRC—colon cancer	1.48e-05	4.87e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—colon cancer	1.48e-05	4.85e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—colon cancer	1.47e-05	4.84e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TYMS—colon cancer	1.47e-05	4.82e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—colon cancer	1.47e-05	4.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—colon cancer	1.46e-05	4.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—colon cancer	1.46e-05	4.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—colon cancer	1.46e-05	4.81e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—colon cancer	1.46e-05	4.79e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—colon cancer	1.46e-05	4.79e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—colon cancer	1.45e-05	4.77e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—colon cancer	1.45e-05	4.75e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—colon cancer	1.45e-05	4.75e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—colon cancer	1.45e-05	4.75e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—colon cancer	1.45e-05	4.75e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—colon cancer	1.45e-05	4.74e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—colon cancer	1.45e-05	4.74e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—colon cancer	1.45e-05	4.74e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—colon cancer	1.44e-05	4.74e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—colon cancer	1.44e-05	4.72e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—colon cancer	1.44e-05	4.72e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—colon cancer	1.44e-05	4.72e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—colon cancer	1.43e-05	4.68e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—colon cancer	1.42e-05	4.68e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—colon cancer	1.42e-05	4.65e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.4e-05	4.6e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—colon cancer	1.4e-05	4.58e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—colon cancer	1.39e-05	4.56e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—colon cancer	1.38e-05	4.54e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.37e-05	4.5e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCB1—colon cancer	1.37e-05	4.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—colon cancer	1.37e-05	4.49e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—colon cancer	1.37e-05	4.49e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—colon cancer	1.37e-05	4.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—colon cancer	1.35e-05	4.43e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—colon cancer	1.35e-05	4.42e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—colon cancer	1.35e-05	4.42e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—colon cancer	1.35e-05	4.42e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TYMS—colon cancer	1.35e-05	4.42e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—colon cancer	1.34e-05	4.41e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—colon cancer	1.34e-05	4.41e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—colon cancer	1.34e-05	4.41e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—colon cancer	1.33e-05	4.38e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—colon cancer	1.33e-05	4.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—colon cancer	1.33e-05	4.38e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—colon cancer	1.33e-05	4.36e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—colon cancer	1.33e-05	4.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—colon cancer	1.32e-05	4.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—colon cancer	1.32e-05	4.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—colon cancer	1.32e-05	4.33e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—colon cancer	1.32e-05	4.32e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—colon cancer	1.3e-05	4.27e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.25e-05	4.11e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—colon cancer	1.25e-05	4.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—colon cancer	1.25e-05	4.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—colon cancer	1.25e-05	4.09e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—colon cancer	1.23e-05	4.05e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—colon cancer	1.23e-05	4.03e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—colon cancer	1.23e-05	4.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—colon cancer	1.22e-05	4.02e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—colon cancer	1.22e-05	4.01e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TYMS—colon cancer	1.2e-05	3.95e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.17e-05	3.85e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—colon cancer	1.16e-05	3.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—colon cancer	1.14e-05	3.75e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—colon cancer	1.14e-05	3.75e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—colon cancer	1.14e-05	3.75e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.14e-05	3.75e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.13e-05	3.71e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—colon cancer	1.13e-05	3.7e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—colon cancer	1.13e-05	3.7e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—colon cancer	1.12e-05	3.67e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—colon cancer	1.12e-05	3.67e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—colon cancer	1.12e-05	3.67e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—colon cancer	1.12e-05	3.67e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—colon cancer	1.11e-05	3.63e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—colon cancer	1.11e-05	3.63e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—colon cancer	1.11e-05	3.63e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TYMS—colon cancer	1.11e-05	3.63e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—colon cancer	1.1e-05	3.62e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TYMS—colon cancer	1.1e-05	3.6e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—colon cancer	1.09e-05	3.58e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—colon cancer	1.06e-05	3.47e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—colon cancer	1.06e-05	3.47e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—colon cancer	1.06e-05	3.47e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—colon cancer	1.04e-05	3.42e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—colon cancer	1.04e-05	3.42e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.04e-05	3.4e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.75e-06	3.2e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—EP300—colon cancer	9.67e-06	3.17e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—colon cancer	9.55e-06	3.13e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—colon cancer	9.54e-06	3.13e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMS—colon cancer	9.37e-06	3.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—colon cancer	9.34e-06	3.07e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—colon cancer	9.34e-06	3.07e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—colon cancer	9.34e-06	3.07e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.26e-06	3.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—colon cancer	9.21e-06	3.02e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—colon cancer	8.52e-06	2.8e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.44e-06	2.77e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—colon cancer	8.19e-06	2.69e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—colon cancer	7.84e-06	2.57e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—colon cancer	7.77e-06	2.55e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—colon cancer	7.51e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—colon cancer	7.36e-06	2.42e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMS—colon cancer	7.23e-06	2.37e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.21e-06	2.37e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—colon cancer	7.15e-06	2.35e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—EP300—colon cancer	6.81e-06	2.24e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—colon cancer	6.7e-06	2.2e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—colon cancer	6.64e-06	2.18e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—EP300—colon cancer	6.25e-06	2.05e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—colon cancer	6.16e-06	2.02e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—colon cancer	6.11e-06	2.01e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—colon cancer	5.84e-06	1.92e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—EP300—colon cancer	5.57e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—colon cancer	5.22e-06	1.71e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—EP300—colon cancer	5.13e-06	1.68e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—colon cancer	5.12e-06	1.68e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—EP300—colon cancer	5.08e-06	1.67e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—colon cancer	5.04e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—colon cancer	4.62e-06	1.52e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—EP300—colon cancer	4.34e-06	1.43e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—colon cancer	4.12e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—colon cancer	4.12e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—colon cancer	4.03e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—colon cancer	3.79e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—colon cancer	3.77e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—colon cancer	3.76e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—colon cancer	3.37e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—EP300—colon cancer	3.35e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—colon cancer	3.21e-06	1.05e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—colon cancer	3.1e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—colon cancer	3.07e-06	1.01e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—colon cancer	2.62e-06	8.62e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—colon cancer	2.48e-06	8.14e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—colon cancer	2.03e-06	6.65e-06	CbGpPWpGaD
